Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.
This report aims to provide a comprehensive presentation of the global market for Human Vaccines Administered Orally, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Vaccines Administered Orally. This report contains market size and forecasts of Human Vaccines Administered Orally in global, including the following market information:
Global Human Vaccines Administered Orally Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Human Vaccines Administered Orally Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Human Vaccines Administered Orally companies in 2022 (%)
The global Human Vaccines Administered Orally market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Rotavirus Vaccine Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Human Vaccines Administered Orally include Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Human Vaccines Administered Orally manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Vaccines Administered Orally Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Human Vaccines Administered Orally Market Segment Percentages, by Type, 2022 (%)
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Global Human Vaccines Administered Orally Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Human Vaccines Administered Orally Market Segment Percentages, by Application, 2022 (%)
Public
Private
Global Human Vaccines Administered Orally Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Human Vaccines Administered Orally Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Vaccines Administered Orally revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Human Vaccines Administered Orally revenues share in global market, 2022 (%)
Key companies Human Vaccines Administered Orally sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Human Vaccines Administered Orally sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Human Vaccines Administered Orally, market overview.
Chapter 2: Global Human Vaccines Administered Orally market size in revenue and volume.
Chapter 3: Detailed analysis of Human Vaccines Administered Orally manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Vaccines Administered Orally in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Human Vaccines Administered Orally capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Human Vaccines Administered Orally Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Human Vaccines Administered Orally Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Human Vaccines Administered Orally Overall Market Size
2.1 Global Human Vaccines Administered Orally Market Size: 2022 VS 2030
2.2 Global Human Vaccines Administered Orally Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Human Vaccines Administered Orally Sales: 2018-2030
3 Company Landscape
3.1 Top Human Vaccines Administered Orally Players in Global Market
3.2 Top Global Human Vaccines Administered Orally Companies Ranked by Revenue
3.3 Global Human Vaccines Administered Orally Revenue by Companies
3.4 Global Human Vaccines Administered Orally Sales by Companies
3.5 Global Human Vaccines Administered Orally Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Human Vaccines Administered Orally Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Human Vaccines Administered Orally Product Type
3.8 Tier 1, Tier 2 and Tier 3 Human Vaccines Administered Orally Players in Global Market
3.8.1 List of Global Tier 1 Human Vaccines Administered Orally Companies
3.8.2 List of Global Tier 2 and Tier 3 Human Vaccines Administered Orally Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Human Vaccines Administered Orally Market Size Markets, 2022 & 2030
4.1.2 Rotavirus Vaccine
4.1.3 Cholera Vaccine
4.1.4 Oral Polio Vaccine
4.2 By Type - Global Human Vaccines Administered Orally Revenue & Forecasts
4.2.1 By Type - Global Human Vaccines Administered Orally Revenue, 2018-2023
4.2.2 By Type - Global Human Vaccines Administered Orally Revenue, 2024-2030
4.2.3 By Type - Global Human Vaccines Administered Orally Revenue Market Share, 2018-2030
4.3 By Type - Global Human Vaccines Administered Orally Sales & Forecasts
4.3.1 By Type - Global Human Vaccines Administered Orally Sales, 2018-2023
4.3.2 By Type - Global Human Vaccines Administered Orally Sales, 2024-2030
4.3.3 By Type - Global Human Vaccines Administered Orally Sales Market Share, 2018-2030
4.4 By Type - Global Human Vaccines Administered Orally Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Human Vaccines Administered Orally Market Size, 2022 & 2030
5.1.2 Public
5.1.3 Private
5.2 By Application - Global Human Vaccines Administered Orally Revenue & Forecasts
5.2.1 By Application - Global Human Vaccines Administered Orally Revenue, 2018-2023
5.2.2 By Application - Global Human Vaccines Administered Orally Revenue, 2024-2030
5.2.3 By Application - Global Human Vaccines Administered Orally Revenue Market Share, 2018-2030
5.3 By Application - Global Human Vaccines Administered Orally Sales & Forecasts
5.3.1 By Application - Global Human Vaccines Administered Orally Sales, 2018-2023
5.3.2 By Application - Global Human Vaccines Administered Orally Sales, 2024-2030
5.3.3 By Application - Global Human Vaccines Administered Orally Sales Market Share, 2018-2030
5.4 By Application - Global Human Vaccines Administered Orally Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Human Vaccines Administered Orally Market Size, 2022 & 2030
6.2 By Region - Global Human Vaccines Administered Orally Revenue & Forecasts
6.2.1 By Region - Global Human Vaccines Administered Orally Revenue, 2018-2023
6.2.2 By Region - Global Human Vaccines Administered Orally Revenue, 2024-2030
6.2.3 By Region - Global Human Vaccines Administered Orally Revenue Market Share, 2018-2030
6.3 By Region - Global Human Vaccines Administered Orally Sales & Forecasts
6.3.1 By Region - Global Human Vaccines Administered Orally Sales, 2018-2023
6.3.2 By Region - Global Human Vaccines Administered Orally Sales, 2024-2030
6.3.3 By Region - Global Human Vaccines Administered Orally Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Human Vaccines Administered Orally Revenue, 2018-2030
6.4.2 By Country - North America Human Vaccines Administered Orally Sales, 2018-2030
6.4.3 US Human Vaccines Administered Orally Market Size, 2018-2030
6.4.4 Canada Human Vaccines Administered Orally Market Size, 2018-2030
6.4.5 Mexico Human Vaccines Administered Orally Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Human Vaccines Administered Orally Revenue, 2018-2030
6.5.2 By Country - Europe Human Vaccines Administered Orally Sales, 2018-2030
6.5.3 Germany Human Vaccines Administered Orally Market Size, 2018-2030
6.5.4 France Human Vaccines Administered Orally Market Size, 2018-2030
6.5.5 U.K. Human Vaccines Administered Orally Market Size, 2018-2030
6.5.6 Italy Human Vaccines Administered Orally Market Size, 2018-2030
6.5.7 Russia Human Vaccines Administered Orally Market Size, 2018-2030
6.5.8 Nordic Countries Human Vaccines Administered Orally Market Size, 2018-2030
6.5.9 Benelux Human Vaccines Administered Orally Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Human Vaccines Administered Orally Revenue, 2018-2030
6.6.2 By Region - Asia Human Vaccines Administered Orally Sales, 2018-2030
6.6.3 China Human Vaccines Administered Orally Market Size, 2018-2030
6.6.4 Japan Human Vaccines Administered Orally Market Size, 2018-2030
6.6.5 South Korea Human Vaccines Administered Orally Market Size, 2018-2030
6.6.6 Southeast Asia Human Vaccines Administered Orally Market Size, 2018-2030
6.6.7 India Human Vaccines Administered Orally Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Human Vaccines Administered Orally Revenue, 2018-2030
6.7.2 By Country - South America Human Vaccines Administered Orally Sales, 2018-2030
6.7.3 Brazil Human Vaccines Administered Orally Market Size, 2018-2030
6.7.4 Argentina Human Vaccines Administered Orally Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Human Vaccines Administered Orally Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Human Vaccines Administered Orally Sales, 2018-2030
6.8.3 Turkey Human Vaccines Administered Orally Market Size, 2018-2030
6.8.4 Israel Human Vaccines Administered Orally Market Size, 2018-2030
6.8.5 Saudi Arabia Human Vaccines Administered Orally Market Size, 2018-2030
6.8.6 UAE Human Vaccines Administered Orally Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Human Vaccines Administered Orally Major Product Offerings
7.1.4 Merck Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 GSK
7.2.1 GSK Company Summary
7.2.2 GSK Business Overview
7.2.3 GSK Human Vaccines Administered Orally Major Product Offerings
7.2.4 GSK Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.2.5 GSK Key News & Latest Developments
7.3 Sanofi
7.3.1 Sanofi Company Summary
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Human Vaccines Administered Orally Major Product Offerings
7.3.4 Sanofi Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.3.5 Sanofi Key News & Latest Developments
7.4 Lanzhou Institute
7.4.1 Lanzhou Institute Company Summary
7.4.2 Lanzhou Institute Business Overview
7.4.3 Lanzhou Institute Human Vaccines Administered Orally Major Product Offerings
7.4.4 Lanzhou Institute Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.4.5 Lanzhou Institute Key News & Latest Developments
7.5 Serum Institute
7.5.1 Serum Institute Company Summary
7.5.2 Serum Institute Business Overview
7.5.3 Serum Institute Human Vaccines Administered Orally Major Product Offerings
7.5.4 Serum Institute Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.5.5 Serum Institute Key News & Latest Developments
7.6 Valneva
7.6.1 Valneva Company Summary
7.6.2 Valneva Business Overview
7.6.3 Valneva Human Vaccines Administered Orally Major Product Offerings
7.6.4 Valneva Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.6.5 Valneva Key News & Latest Developments
7.7 Shanghai United Cell
7.7.1 Shanghai United Cell Company Summary
7.7.2 Shanghai United Cell Business Overview
7.7.3 Shanghai United Cell Human Vaccines Administered Orally Major Product Offerings
7.7.4 Shanghai United Cell Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.7.5 Shanghai United Cell Key News & Latest Developments
7.8 Bibcol
7.8.1 Bibcol Company Summary
7.8.2 Bibcol Business Overview
7.8.3 Bibcol Human Vaccines Administered Orally Major Product Offerings
7.8.4 Bibcol Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.8.5 Bibcol Key News & Latest Developments
7.9 PaxVax
7.9.1 PaxVax Company Summary
7.9.2 PaxVax Business Overview
7.9.3 PaxVax Human Vaccines Administered Orally Major Product Offerings
7.9.4 PaxVax Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.9.5 PaxVax Key News & Latest Developments
7.10 Vabiotech
7.10.1 Vabiotech Company Summary
7.10.2 Vabiotech Business Overview
7.10.3 Vabiotech Human Vaccines Administered Orally Major Product Offerings
7.10.4 Vabiotech Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.10.5 Vabiotech Key News & Latest Developments
7.11 Tiantan Biological
7.11.1 Tiantan Biological Company Summary
7.11.2 Tiantan Biological Human Vaccines Administered Orally Business Overview
7.11.3 Tiantan Biological Human Vaccines Administered Orally Major Product Offerings
7.11.4 Tiantan Biological Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.11.5 Tiantan Biological Key News & Latest Developments
7.12 EuBiologics
7.12.1 EuBiologics Company Summary
7.12.2 EuBiologics Human Vaccines Administered Orally Business Overview
7.12.3 EuBiologics Human Vaccines Administered Orally Major Product Offerings
7.12.4 EuBiologics Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.12.5 EuBiologics Key News & Latest Developments
7.13 Panacea Biotec Ltd
7.13.1 Panacea Biotec Ltd Company Summary
7.13.2 Panacea Biotec Ltd Human Vaccines Administered Orally Business Overview
7.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Major Product Offerings
7.13.4 Panacea Biotec Ltd Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.13.5 Panacea Biotec Ltd Key News & Latest Developments
7.14 Bio-Med
7.14.1 Bio-Med Company Summary
7.14.2 Bio-Med Business Overview
7.14.3 Bio-Med Human Vaccines Administered Orally Major Product Offerings
7.14.4 Bio-Med Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.14.5 Bio-Med Key News & Latest Developments
7.15 Halfkin Bio-Pharmaceuticals
7.15.1 Halfkin Bio-Pharmaceuticals Company Summary
7.15.2 Halfkin Bio-Pharmaceuticals Business Overview
7.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Major Product Offerings
7.15.4 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales and Revenue in Global (2018-2023)
7.15.5 Halfkin Bio-Pharmaceuticals Key News & Latest Developments
8 Global Human Vaccines Administered Orally Production Capacity, Analysis
8.1 Global Human Vaccines Administered Orally Production Capacity, 2018-2030
8.2 Human Vaccines Administered Orally Production Capacity of Key Manufacturers in Global Market
8.3 Global Human Vaccines Administered Orally Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Human Vaccines Administered Orally Supply Chain Analysis
10.1 Human Vaccines Administered Orally Industry Value Chain
10.2 Human Vaccines Administered Orally Upstream Market
10.3 Human Vaccines Administered Orally Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Human Vaccines Administered Orally Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Human Vaccines Administered Orally in Global Market
Table 2. Top Human Vaccines Administered Orally Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Human Vaccines Administered Orally Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Human Vaccines Administered Orally Revenue Share by Companies, 2018-2023
Table 5. Global Human Vaccines Administered Orally Sales by Companies, (K Units), 2018-2023
Table 6. Global Human Vaccines Administered Orally Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Human Vaccines Administered Orally Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Human Vaccines Administered Orally Product Type
Table 9. List of Global Tier 1 Human Vaccines Administered Orally Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Human Vaccines Administered Orally Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Human Vaccines Administered Orally Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Human Vaccines Administered Orally Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Human Vaccines Administered Orally Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Human Vaccines Administered Orally Sales (K Units), 2018-2023
Table 15. By Type - Global Human Vaccines Administered Orally Sales (K Units), 2024-2030
Table 16. By Application ? Global Human Vaccines Administered Orally Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Human Vaccines Administered Orally Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Human Vaccines Administered Orally Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Human Vaccines Administered Orally Sales (K Units), 2018-2023
Table 20. By Application - Global Human Vaccines Administered Orally Sales (K Units), 2024-2030
Table 21. By Region ? Global Human Vaccines Administered Orally Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Human Vaccines Administered Orally Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Human Vaccines Administered Orally Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Human Vaccines Administered Orally Sales (K Units), 2018-2023
Table 25. By Region - Global Human Vaccines Administered Orally Sales (K Units), 2024-2030
Table 26. By Country - North America Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Human Vaccines Administered Orally Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Human Vaccines Administered Orally Sales, (K Units), 2018-2023
Table 29. By Country - North America Human Vaccines Administered Orally Sales, (K Units), 2024-2030
Table 30. By Country - Europe Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Human Vaccines Administered Orally Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Human Vaccines Administered Orally Sales, (K Units), 2018-2023
Table 33. By Country - Europe Human Vaccines Administered Orally Sales, (K Units), 2024-2030
Table 34. By Region - Asia Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Human Vaccines Administered Orally Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Human Vaccines Administered Orally Sales, (K Units), 2018-2023
Table 37. By Region - Asia Human Vaccines Administered Orally Sales, (K Units), 2024-2030
Table 38. By Country - South America Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Human Vaccines Administered Orally Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Human Vaccines Administered Orally Sales, (K Units), 2018-2023
Table 41. By Country - South America Human Vaccines Administered Orally Sales, (K Units), 2024-2030
Table 42. By Country - Middle East & Africa Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Human Vaccines Administered Orally Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Human Vaccines Administered Orally Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Human Vaccines Administered Orally Sales, (K Units), 2024-2030
Table 46. Merck Company Summary
Table 47. Merck Human Vaccines Administered Orally Product Offerings
Table 48. Merck Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Merck Key News & Latest Developments
Table 50. GSK Company Summary
Table 51. GSK Human Vaccines Administered Orally Product Offerings
Table 52. GSK Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. GSK Key News & Latest Developments
Table 54. Sanofi Company Summary
Table 55. Sanofi Human Vaccines Administered Orally Product Offerings
Table 56. Sanofi Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Sanofi Key News & Latest Developments
Table 58. Lanzhou Institute Company Summary
Table 59. Lanzhou Institute Human Vaccines Administered Orally Product Offerings
Table 60. Lanzhou Institute Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Lanzhou Institute Key News & Latest Developments
Table 62. Serum Institute Company Summary
Table 63. Serum Institute Human Vaccines Administered Orally Product Offerings
Table 64. Serum Institute Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Serum Institute Key News & Latest Developments
Table 66. Valneva Company Summary
Table 67. Valneva Human Vaccines Administered Orally Product Offerings
Table 68. Valneva Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Valneva Key News & Latest Developments
Table 70. Shanghai United Cell Company Summary
Table 71. Shanghai United Cell Human Vaccines Administered Orally Product Offerings
Table 72. Shanghai United Cell Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Shanghai United Cell Key News & Latest Developments
Table 74. Bibcol Company Summary
Table 75. Bibcol Human Vaccines Administered Orally Product Offerings
Table 76. Bibcol Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Bibcol Key News & Latest Developments
Table 78. PaxVax Company Summary
Table 79. PaxVax Human Vaccines Administered Orally Product Offerings
Table 80. PaxVax Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. PaxVax Key News & Latest Developments
Table 82. Vabiotech Company Summary
Table 83. Vabiotech Human Vaccines Administered Orally Product Offerings
Table 84. Vabiotech Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Vabiotech Key News & Latest Developments
Table 86. Tiantan Biological Company Summary
Table 87. Tiantan Biological Human Vaccines Administered Orally Product Offerings
Table 88. Tiantan Biological Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Tiantan Biological Key News & Latest Developments
Table 90. EuBiologics Company Summary
Table 91. EuBiologics Human Vaccines Administered Orally Product Offerings
Table 92. EuBiologics Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. EuBiologics Key News & Latest Developments
Table 94. Panacea Biotec Ltd Company Summary
Table 95. Panacea Biotec Ltd Human Vaccines Administered Orally Product Offerings
Table 96. Panacea Biotec Ltd Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Panacea Biotec Ltd Key News & Latest Developments
Table 98. Bio-Med Company Summary
Table 99. Bio-Med Human Vaccines Administered Orally Product Offerings
Table 100. Bio-Med Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. Bio-Med Key News & Latest Developments
Table 102. Halfkin Bio-Pharmaceuticals Company Summary
Table 103. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Offerings
Table 104. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 105. Halfkin Bio-Pharmaceuticals Key News & Latest Developments
Table 106. Human Vaccines Administered Orally Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 107. Global Human Vaccines Administered Orally Capacity Market Share of Key Manufacturers, 2021-2023
Table 108. Global Human Vaccines Administered Orally Production by Region, 2018-2023 (K Units)
Table 109. Global Human Vaccines Administered Orally Production by Region, 2024-2030 (K Units)
Table 110. Human Vaccines Administered Orally Market Opportunities & Trends in Global Market
Table 111. Human Vaccines Administered Orally Market Drivers in Global Market
Table 112. Human Vaccines Administered Orally Market Restraints in Global Market
Table 113. Human Vaccines Administered Orally Raw Materials
Table 114. Human Vaccines Administered Orally Raw Materials Suppliers in Global Market
Table 115. Typical Human Vaccines Administered Orally Downstream
Table 116. Human Vaccines Administered Orally Downstream Clients in Global Market
Table 117. Human Vaccines Administered Orally Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Human Vaccines Administered Orally Segment by Type in 2022
Figure 2. Human Vaccines Administered Orally Segment by Application in 2022
Figure 3. Global Human Vaccines Administered Orally Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Human Vaccines Administered Orally Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Human Vaccines Administered Orally Revenue, 2018-2030 (US$, Mn)
Figure 7. Human Vaccines Administered Orally Sales in Global Market: 2018-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Human Vaccines Administered Orally Revenue in 2022
Figure 9. By Type - Global Human Vaccines Administered Orally Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Human Vaccines Administered Orally Revenue Market Share, 2018-2030
Figure 11. By Type - Global Human Vaccines Administered Orally Sales Market Share, 2018-2030
Figure 12. By Type - Global Human Vaccines Administered Orally Price (US$/Unit), 2018-2030
Figure 13. By Application - Global Human Vaccines Administered Orally Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Human Vaccines Administered Orally Revenue Market Share, 2018-2030
Figure 15. By Application - Global Human Vaccines Administered Orally Sales Market Share, 2018-2030
Figure 16. By Application - Global Human Vaccines Administered Orally Price (US$/Unit), 2018-2030
Figure 17. By Region - Global Human Vaccines Administered Orally Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Human Vaccines Administered Orally Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Human Vaccines Administered Orally Revenue Market Share, 2018-2030
Figure 20. By Region - Global Human Vaccines Administered Orally Sales Market Share, 2018-2030
Figure 21. By Country - North America Human Vaccines Administered Orally Revenue Market Share, 2018-2030
Figure 22. By Country - North America Human Vaccines Administered Orally Sales Market Share, 2018-2030
Figure 23. US Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Human Vaccines Administered Orally Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Human Vaccines Administered Orally Sales Market Share, 2018-2030
Figure 28. Germany Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 29. France Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Human Vaccines Administered Orally Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Human Vaccines Administered Orally Sales Market Share, 2018-2030
Figure 37. China Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 41. India Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Human Vaccines Administered Orally Revenue Market Share, 2018-2030
Figure 43. By Country - South America Human Vaccines Administered Orally Sales Market Share, 2018-2030
Figure 44. Brazil Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Human Vaccines Administered Orally Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Human Vaccines Administered Orally Sales Market Share, 2018-2030
Figure 48. Turkey Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Human Vaccines Administered Orally Revenue, (US$, Mn), 2018-2030
Figure 52. Global Human Vaccines Administered Orally Production Capacity (K Units), 2018-2030
Figure 53. The Percentage of Production Human Vaccines Administered Orally by Region, 2022 VS 2030
Figure 54. Human Vaccines Administered Orally Industry Value Chain
Figure 55. Marketing Channels
